GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Tax Expense

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Tax Expense : ¥-13.5 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co Tax Expense?

Wuhan Hiteck Biological Pharma Co's tax expense for the months ended in Sep. 2024 was ¥-4.3 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-13.5 Mil.


Wuhan Hiteck Biological Pharma Co Tax Expense Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co Tax Expense Chart

Wuhan Hiteck Biological Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.42 -11.69 -9.56 0.07 -23.74

Wuhan Hiteck Biological Pharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.66 -4.19 -10.95 5.92 -4.31

Wuhan Hiteck Biological Pharma Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-13.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hiteck Biological Pharma Co  (SZSE:300683) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Wuhan Hiteck Biological Pharma Co Tax Expense Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Hiteck Biological Pharma Co Business Description

Traded in Other Exchanges
N/A
Address
Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Executives
Yan Jie Director
Li Sheng Qiang Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines